NanoViricides, Inc. NEW (NNVC) News

NanoViricides, Inc. NEW (NNVC): $1.89

0.01 (+0.53%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NNVC to Watchlist
Sign Up

Industry: Biotech


Ranked

of 454

in industry

Filter NNVC News Items

NNVC News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest NNVC News From Around the Web

Below are the latest news stories about Nanoviricides Inc that investors may wish to consider to help them evaluate NNVC as an investment opportunity.

NanoViricides (NYSEAMERICAN:NNVC) Issues Earnings Results

NanoViricides (NYSEAMERICAN:NNVC) issued its earnings results on Monday. The company reported ($0.23) EPS for the quarter, missing the Zacks consensus estimate of ($0.20) by ($0.03), Fidelity Earnings reports. Shares of NNVC stock opened at $4.76 on Thursday. The stock has a market capitalization of $54.81 million, a price-to-earnings ratio of -5.88 and a beta of []

Dakota Financial News | November 18, 2021

NanoViricides, Inc. (NYSEAMERICAN:NNVC) Short Interest Update

NanoViricides, Inc. (NYSEAMERICAN:NNVC) was the target of a large drop in short interest in October. As of October 29th, there was short interest totalling 494,500 shares, a drop of 36.4% from the October 14th total of 777,000 shares. Currently, 4.5% of the companys stock are short sold. Based on an average trading volume of 2,500,000 []

Transcript Daily | November 18, 2021

NanoViricides, Inc.: NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards Clinical Trials

SHELTON, CT / ACCESSWIRE / November 16, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel n

FinanzNachrichten | November 16, 2021

NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards Clinical Trials

SHELTON, CT / ACCESSWIRE / November 16, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), has filed its quarterly report for its first quarter of financial year 2022 with the Securities and Exchange Commission.

Yahoo | November 16, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Welcome back, trader!

William White on InvestorPlace | November 15, 2021

NanoViricides, Inc.: NanoViricides Completes Oral Gummies and Lung Inhalation Formulations Development for its Non-Mutagenic, Safe, Broad-Spectrum COVID-19 Clinical Drug Candidate, NV-CoV-2

SHELTON, CT / ACCESSWIRE / November 15, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomed

FinanzNachrichten | November 15, 2021

EXCLUSIVE: NanoViricides Completes Oral Gummies, Lung Inhalation Formulations For COVID-19 Treatment

NanoViricides, Inc. (NYSE: NNVC) announced Monday it has developed an oral gummies formulation of its COVID-19 Drug Candidate NV-CoV-2 to benefit non-hospitalized patients. The company believes the formulation may have advantages in terms of drug bioavailability over oral pills, because of partial sublingual absorption that avoids the gastrointestinal tract. What To Know: NanoViricides says this oral gummies formulation would be attractive to patients, especially children, over oral pills. The c

Yahoo | November 15, 2021

NanoViricides Completes Oral Gummies and Lung Inhalation Formulations Development for its Non-Mutagenic, Safe, Broad-Spectrum COVID-19 Clinical Drug Candidate, NV-CoV-2

SHELTON, CT / ACCESSWIRE / November 15, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, announced today that it has developed oral gummies formulations of its Pan-Coronavirus COVID-19 Drug Candidate NV-CoV-2 to benefit non-hospitalized patients.

Yahoo | November 15, 2021

EXCLUSIVE: NanoViricides Develops Chewable Pills, Lung Inhalation Formulations For COVID-19 Candidate

NanoViricides Inc (NYSE: NNVC) has developed oral gummies formulations of its Pan-Coronavirus COVID-19 Drug Candidate NV-CoV-2 to benefit non-hospitalized patients. What Happened: NanoViricides completed the development of an oral gummies (chewable gel) formulation of NV-CoV-2 for the benefit of symptomatic non-hospitalized patients. The Company believes that this formulation may have advantages in drug bioavailability over oral pills because of partial sublingual absorption that avoids the gast

Yahoo | November 15, 2021

NanoViricides Inc. (AMEX: NNVC): Is It Stable And Growing?

NanoViricides Inc. (AMEX:NNVC) shares, rose in value on Friday, 11/05/21, with the stock price down by -11.92% to the previous days close as strong demand from buyers drove the stock to $4.73. Actively observing the price movement in the last trading, the stock closed the session at $5.37, falling within a range of $4.71 and NanoViricides Inc. (AMEX: NNVC): Is It Stable And Growing? Read More »

Stocks Register | November 6, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5958 seconds.